OpenAI unveiled JalapeñO, a custom processor reportedly outperforming Nvidia's Blackwell chips in testing, while Nvidia simultaneously raised prices 15% on existing AI customers. This dual pressure on the vendor landscape creates immediate complexity for healthcare organizations planning AI infrastructure. Healthcare systems evaluating inference hardware for clinical applications now face competing options that could significantly impact deployment costs and model performance. The shift toward custom silicon adoption signals that dependence on single-vendor solutions carries financial and strategic risk for healthcare IT planning. Consulting teams should reassess client infrastructure roadmaps given this acceleration in alternative chip development and pricing volatility.